$BIOCQ
Biocept Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023042468 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $600.0K
YoY Change -94.34%
Cost Of Revenue $2.550M
YoY Change -68.22%
Gross Profit -$1.950M
YoY Change -175.67%
Gross Profit Margin -325.0%
Selling, General & Admin $3.744M
YoY Change -37.14%
% of Gross Profit
Research & Development $409.0K
YoY Change -76.34%
% of Gross Profit
Depreciation & Amortization $517.0K
YoY Change 27.65%
% of Gross Profit
Operating Expenses $4.153M
YoY Change -45.96%
Operating Profit -$6.114M
YoY Change 19.95%
Interest Expense $50.00K
YoY Change -132.26%
% of Operating Profit
Other Income/Expense, Net $2.483M
YoY Change -1701.94%
Pretax Income -$3.631M
YoY Change -30.86%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.631M
YoY Change -30.86%
Net Earnings / Revenue -605.17%
Basic Earnings Per Share -$3.50
Diluted Earnings Per Share -$3.50
COMMON SHARES
Basic Shares Outstanding 2.626M 17.78M
Diluted Shares Outstanding 1.037M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.633M
YoY Change -71.07%
Cash & Equivalents $6.633M
Short-Term Investments
Other Short-Term Assets $876.0K
YoY Change -28.49%
Inventory $551.0K
Prepaid Expenses
Receivables $800.0K
Other Receivables $0.00
Total Short-Term Assets $8.860M
YoY Change -79.76%
LONG-TERM ASSETS
Property, Plant & Equipment $2.395M
YoY Change -11.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $386.0K
YoY Change -22.18%
Total Long-Term Assets $13.24M
YoY Change -7.8%
TOTAL ASSETS
Total Short-Term Assets $8.860M
Total Long-Term Assets $13.24M
Total Assets $22.10M
YoY Change -61.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.467M
YoY Change -69.63%
Accrued Expenses $1.529M
YoY Change -44.14%
Deferred Revenue
YoY Change
Short-Term Debt $526.0K
YoY Change 0.38%
Long-Term Debt Due $815.0K
YoY Change -22.6%
Total Short-Term Liabilities $4.902M
YoY Change -49.01%
LONG-TERM LIABILITIES
Long-Term Debt $836.0K
YoY Change -12.64%
Other Long-Term Liabilities $16.08M
YoY Change 6.34%
Total Long-Term Liabilities $16.91M
YoY Change 5.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.902M
Total Long-Term Liabilities $16.91M
Total Liabilities $21.81M
YoY Change -15.08%
SHAREHOLDERS EQUITY
Retained Earnings -$309.2M
YoY Change 12.68%
Common Stock $309.5M
YoY Change 0.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $290.0K
YoY Change
Total Liabilities & Shareholders Equity $22.10M
YoY Change -61.98%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.631M
YoY Change -30.86%
Depreciation, Depletion And Amortization $517.0K
YoY Change 27.65%
Cash From Operating Activities -$3.086M
YoY Change -23.61%
INVESTING ACTIVITIES
Capital Expenditures $97.00K
YoY Change -144.7%
Acquisitions
YoY Change
Other Investing Activities $75.00K
YoY Change
Cash From Investing Activities -$22.00K
YoY Change -89.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.967M
YoY Change -878.74%
NET CHANGE
Cash From Operating Activities -3.086M
Cash From Investing Activities -22.00K
Cash From Financing Activities 2.967M
Net Change In Cash -141.0K
YoY Change -96.96%
FREE CASH FLOW
Cash From Operating Activities -$3.086M
Capital Expenditures $97.00K
Free Cash Flow -$3.183M
YoY Change -16.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001044378
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36284
dei Entity Registrant Name
EntityRegistrantName
Biocept, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0943522
dei Entity Address Address Line1
EntityAddressAddressLine1
9955 Mesa Rim Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
320-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
BIOC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2626026
CY2023Q2 us-gaap Cash
Cash
6633000
CY2022Q4 us-gaap Cash
Cash
12897000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
800000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2151000
CY2023Q2 us-gaap Inventory Net
InventoryNet
551000
CY2022Q4 us-gaap Inventory Net
InventoryNet
757000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
876000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
538000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
8860000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16343000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2395000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2572000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8190000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8486000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2272000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
3086000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
386000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
386000
CY2023Q2 us-gaap Assets
Assets
22103000
CY2022Q4 us-gaap Assets
Assets
30873000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1467000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1523000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1529000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2249000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
565000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
518000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
815000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1099000
CY2023Q2 bioc Financial Guarantee Insurance Contracts Premiums Payable
FinancialGuaranteeInsuranceContractsPremiumsPayable
526000
CY2022Q4 bioc Financial Guarantee Insurance Contracts Premiums Payable
FinancialGuaranteeInsuranceContractsPremiumsPayable
117000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4902000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5506000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8849000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9175000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
836000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1200000
CY2023Q2 bioc Payor Liability
PayorLiability
6149000
CY2022Q4 bioc Payor Liability
PayorLiability
6132000
CY2023Q2 bioc Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
1077000
CY2023Q2 us-gaap Liabilities
Liabilities
21813000
CY2022Q4 us-gaap Liabilities
Liabilities
22013000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2090
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2090
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2090
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2090
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2407381
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2407381
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
568994
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
568994
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
309503000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
307298000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309213000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298438000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
290000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8860000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22103000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30873000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
589000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5819000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1262000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25763000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
2550000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
8023000
us-gaap Cost Of Revenue
CostOfRevenue
5578000
us-gaap Cost Of Revenue
CostOfRevenue
18357000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
409000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1729000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1449000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3574000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3494000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4300000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6482000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10556000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
250000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1656000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
965000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5314000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
6703000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
15708000
us-gaap Costs And Expenses
CostsAndExpenses
14474000
us-gaap Costs And Expenses
CostsAndExpenses
37801000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6114000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9889000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13212000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12038000
CY2023Q2 us-gaap Interest Expense
InterestExpense
50000
CY2022Q2 us-gaap Interest Expense
InterestExpense
155000
us-gaap Interest Expense
InterestExpense
96000
us-gaap Interest Expense
InterestExpense
217000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2442000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2442000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2483000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-155000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2437000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-217000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3631000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10044000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10775000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12255000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3631000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10044000
us-gaap Net Income Loss
NetIncomeLoss
-10775000
us-gaap Net Income Loss
NetIncomeLoss
-12255000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3631000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10044000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10775000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12255000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1036529
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
563528
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
813180
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
562561
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1036529
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
563528
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
813180
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
562561
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21.78
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-21.78
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8860000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
316000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7144000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2428000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
209000
CY2023Q2 bioc Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
800000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3631000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
290000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1759000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2210000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37029000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
585000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10044000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
27664000
us-gaap Profit Loss
ProfitLoss
-10775000
us-gaap Profit Loss
ProfitLoss
-12255000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
984000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
810000
bioc Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
296000
bioc Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
268000
us-gaap Share Based Compensation
ShareBasedCompensation
525000
us-gaap Share Based Compensation
ShareBasedCompensation
2344000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-36000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
125000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2000
bioc Transaction Costs Allocated To Warrants
TransactionCostsAllocatedToWarrants
505000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2442000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1351000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1203000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-206000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-402000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
308000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2852000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-389000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-281000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-279000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-230000
bioc Increase Decrease In Payor Liability
IncreaseDecreaseInPayorLiability
17000
bioc Increase Decrease In Payor Liability
IncreaseDecreaseInPayorLiability
5654000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9280000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4972000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
188000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
315000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
75000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-113000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-315000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
396000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94000
bioc Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
3558000
bioc Finance Lease Principal Payments Net
FinanceLeasePrincipalPaymentsNet
394000
bioc Finance Lease Principal Payments Net
FinanceLeasePrincipalPaymentsNet
501000
bioc Payments On Financial Guarantee Insurance Contracts Premium
PaymentsOnFinancialGuaranteeInsuranceContractsPremium
431000
bioc Payments On Financial Guarantee Insurance Contracts Premium
PaymentsOnFinancialGuaranteeInsuranceContractsPremium
242000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3129000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-649000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6264000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5936000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12897000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28864000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6633000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22928000
us-gaap Interest Paid Net
InterestPaidNet
96000
us-gaap Interest Paid Net
InterestPaidNet
217000
bioc Initial Measurement Of Warrants Issued In Connection With Offering
InitialMeasurementOfWarrantsIssuedInConnectionWithOffering
4319000
bioc Unpaid Issuance Costs In Accounts Payable And Accrued Liabilities
UnpaidIssuanceCostsInAccountsPayableAndAccruedLiabilities
741000
bioc Fair Value Of Cashless Warrants Exercised
FairValueOfCashlessWarrantsExercised
800000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
45000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
361000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
589000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5819000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1262000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25763000
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
0
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3183000
CY2023Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
161000
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
160000
CY2023Q2 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
4042000
CY2022Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
3824000
CY2023Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
700000
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
689000
CY2023Q2 us-gaap Cash
Cash
6600000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309200000
us-gaap Net Income Loss
NetIncomeLoss
-10800000
us-gaap Net Income Loss
NetIncomeLoss
-12300000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
600000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1300000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25800000
CY2023Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-05-25
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y10M24D
CY2023Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
970000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1564000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
110000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
401000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
36000
CY2023Q2 us-gaap Inventory Gross
InventoryGross
1086000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2001000
CY2023Q2 us-gaap Inventory Adjustments
InventoryAdjustments
535000
CY2022Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1244000
CY2023Q2 us-gaap Inventory Net
InventoryNet
551000
CY2022Q4 us-gaap Inventory Net
InventoryNet
757000
CY2023Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3781000
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
39000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
39000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8723000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7895000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6328000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5323000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2395000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2572000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
792000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1766000
CY2023Q2 bioc Accrued Issuance Costs Current
AccruedIssuanceCostsCurrent
310000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
427000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
483000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1529000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2249000
CY2023Q2 bioc Finance Leased Assets Gross
FinanceLeasedAssetsGross
4800000
CY2022Q4 bioc Finance Leased Assets Gross
FinanceLeasedAssetsGross
7200000
CY2023Q2 bioc Finance Lease Lessee Accumulated Deprecation
FinanceLeaseLesseeAccumulatedDeprecation
2500000
CY2022Q4 bioc Finance Lease Lessee Accumulated Deprecation
FinanceLeaseLesseeAccumulatedDeprecation
4100000
CY2023Q2 bioc Finance Lease Depreciation Expense
FinanceLeaseDepreciationExpense
300000
CY2022Q2 bioc Finance Lease Depreciation Expense
FinanceLeaseDepreciationExpense
200000
bioc Finance Lease Depreciation Expense
FinanceLeaseDepreciationExpense
600000
bioc Finance Lease Depreciation Expense
FinanceLeaseDepreciationExpense
400000
bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
23000000
bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
48
bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
600000
CY2023Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
28000000
bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2027-06
bioc Proceeds From Lender To Fund Finance Lease Obligation
ProceedsFromLenderToFundFinanceLeaseObligation
107000000
bioc Finance Lease Transaction Number Of Installment Payments
FinanceLeaseTransactionNumberOfInstallmentPayments
60
bioc Finance Lease Transaction Monthly Rental Payments
FinanceLeaseTransactionMonthlyRentalPayments
2000000
CY2022Q2 bioc Finance Lease Transaction Amount Due Under Financing Arrangement
FinanceLeaseTransactionAmountDueUnderFinancingArrangement
111000000
bioc Finance Lease Transaction Commitment Obligation Month And Year
FinanceLeaseTransactionCommitmentObligationMonthAndYear
2027-08
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
310000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
214000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
578000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
440000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
41000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
58000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
90000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
106000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
415000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
414000
us-gaap Operating Lease Cost
OperatingLeaseCost
829000
us-gaap Operating Lease Cost
OperatingLeaseCost
829000
CY2023Q2 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
766000
CY2022Q2 bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
686000
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1497000
bioc Operating And Finance Lease Cost
OperatingAndFinanceLeaseCost
1375000
CY2023Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
484000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
816000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
729000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1672000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
404000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1715000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
199000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1762000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
17000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1805000
CY2023Q2 bioc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6714000
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1833000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14484000
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
182000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5070000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
1651000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9414000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
90000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
106000
us-gaap Operating Lease Payments
OperatingLeasePayments
813000
us-gaap Operating Lease Payments
OperatingLeasePayments
791000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
546000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
501000
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.084
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
bioc Share Based Compensation Arrangement By Share Based Payment Award Number Of Equity Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans
2
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
75336
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
98.46
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
35313
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
109.44
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
40023
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
88.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
39659
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
89.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M12D
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M2D
CY2023Q2 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2022Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1144734
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
136878
CY2023Q2 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
100000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-042468-index-headers.html Edgar Link pending
0000950170-23-042468-index.html Edgar Link pending
0000950170-23-042468.txt Edgar Link pending
0000950170-23-042468-xbrl.zip Edgar Link pending
bioc-20230630.htm Edgar Link pending
bioc-20230630.xsd Edgar Link pending
bioc-ex31_1.htm Edgar Link pending
bioc-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
bioc-20230630_cal.xml Edgar Link unprocessable
bioc-20230630_def.xml Edgar Link unprocessable
bioc-20230630_pre.xml Edgar Link unprocessable
bioc-20230630_lab.xml Edgar Link unprocessable
bioc-20230630_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending